financetom
Business
financetom
/
Business
/
Ford reaffirms annual EBIT guidance after latest aluminum supplier fire
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ford reaffirms annual EBIT guidance after latest aluminum supplier fire
Nov 21, 2025 11:37 AM

DETROIT (Reuters) -Ford Motor ( F ) on Friday stood by its annual EBIT guidance of $6 billion to $6.5 billion for this year following another fire this week at aluminum supplier Novelis' New York plant.

Ford's stock rose about 4% during Friday's session, extending gains after the automaker reaffirmed the outlook it had already revised because of production disruptions from a devastating blaze at the supplier's plant in September. 

In October, the carmaker cut its profit forecast, citing a gross hit of up to $2 billion from the incident. Ford expects to offset about $1 billion of that next year by increasing production at certain truck plants, it said in October.

Ford is a major customer of Novelis because its trucks use a largely aluminum body. The automaker indefinitely paused production of its F-150 Lightning electric pickup in Michigan after the September fire at Novelis' Oswego, New York, factory. Output of its lucrative gas-powered F-150 lineup has also been disrupted.

In October, Novelis said it planned to restart operations at the affected part of the plant by the end of December, an acceleration from its previous projection of resuming by the first quarter of 2026. The Ford statement on Friday did not outline any changes to that timeline.

"Novelis and Ford will continue to provide updates as further details become available," the statement said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
Chevron seeks diversified approach to refinery investment
Chevron seeks diversified approach to refinery investment
Sep 8, 2025
SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025
04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...
Copyright 2023-2025 - www.financetom.com All Rights Reserved